| Not Yet Recruiting | Clonal Hematopoiesis of Immunological Significance NCT05969821 | Assistance Publique - Hôpitaux de Paris | — |
| Recruiting | Prognostic Value of NETosis Markers for Thrombosis During Myeloproliferative Neoplasms (AVATARE) NCT07119970 | University Hospital, Bordeaux | N/A |
| Recruiting | MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People NCT07362225 | MPN Research Foundation | — |
| Recruiting | Trial of 2 Step ATG for Acute GVHD Prevention Post Myeloablative Allogeneic Stem Cell Transplant NCT06315309 | University of Alabama at Birmingham | Phase 2 |
| Recruiting | Trial of 2 Step ATG for Prevention of Acute GVHD Post Allogeneic Stem Cell Transplant NCT06265584 | University of Alabama at Birmingham | Phase 2 |
| Recruiting | Feasibility of a Multi-omics Platform for Hematological Malignancies NCT07445438 | Azienda Ospedaliero-Universitaria di Parma | N/A |
| Active Not Recruiting | Characterization of Myeloproliferative Neoplasia With a Mutated IDH, SRSF2 or SF3B1 Allele (CARPEDIEM) NCT06481345 | University Hospital, Brest | — |
| Recruiting | I Can Move With Purpose Now! A Pilot Lifestyle Intervention Study in Myeloproliferative Neoplasm Patients NCT05842603 | Massachusetts General Hospital | N/A |
| Recruiting | Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation NCT06138587 | Dana-Farber Cancer Institute | Phase 1 |
| Active Not Recruiting | Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients NCT05823571 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 1 |
| Recruiting | INTEGRATIVE "MULTI-OMICS" AND FUNCTIONAL PLATFORM FOR THE COMPLETE DIAGNOSTIC CHARACTERIZATION OF TUMORS: THE NCT07403630 | Azienda Ospedaliero-Universitaria di Parma | N/A |
| Unknown | In Vitro Drug Sensitivity Testing of Fresh Human Samples NCT05001386 | Hospices Civils de Lyon | N/A |
| Recruiting | Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft NCT05088356 | Stanford University | Phase 1 |
| Recruiting | Chemogenomic Profiling in Hematological Malignancies (HEM-Profiling 2021) NCT07445984 | Azienda Ospedaliero-Universitaria di Parma | N/A |
| Terminated | Thrombosomes® in Bleeding Thrombocytopenic Patients Study NCT04631211 | Cellphire Therapeutics, Inc. | Phase 2 |
| Active Not Recruiting | An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neop NCT04717414 | Celgene | Phase 3 |
| Withdrawn | HA-1H TCR T Cell for Relapsed/Persistent Hematologic Malignancies After Allogeneic Stem Cell Transplantation NCT04464889 | Medigene AG | Phase 1 |
| Recruiting | SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry NCT03452774 | Massive Bio, Inc. | — |
| Withdrawn | Cell Cycle Regulatory Gene Study in Patients With Myeloproliferative Disorders NCT02663648 | Shandong University | — |
| Terminated | Exploring the Mechanisms of Resistance of Stem Cells Myeloproliferative Opposite of Tyrosine Kinase Inhibitors NCT02766153 | Centre Hospitalier Universitaire de Nice | — |
| Completed | PTCy and Ruxolitinib GVHD Prophylaxis in Myelofibrosis NCT02806375 | St. Petersburg State Pavlov Medical University | Phase 1 / Phase 2 |
| Completed | Pulmonary Hypertension in Patients With Myeloproliferative Neoplasms NCT02580903 | Odense University Hospital | — |
| Unknown | Outcomes in Patients With Myeloproliferative Neoplasm and Splanchnic Vein Thrombosis NCT04631458 | Royal Free Hospital NHS Foundation Trust | — |
| Completed | A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative NCT02158858 | Constellation Pharmaceuticals | Phase 1 / Phase 2 |
| Unknown | Predictive Clinical and Biological Parameters in Acute Leukemia, Myelodysplastic Syndromes and Myeloproliferat NCT02320656 | Institut Paoli-Calmettes | N/A |
| Unknown | Irradiation-based Myeloablative Conditioning Followed by Treg/Tcon Immunotherapy in HSCT NCT03977103 | University Of Perugia | Phase 2 |
| Completed | A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF NCT01787552 | Novartis Pharmaceuticals | Phase 1 / Phase 2 |
| Completed | A Phase 1, Open-Label, Dose-Escalation & Expanded Cohort, Continuous IV Infusion, Multi-center Study of the Sa NCT01684150 | Epizyme, Inc. | Phase 1 |
| Completed | Screening for Pulmonary Vascular Changes in Patients With Chronic Myeloproliferative Diseases NCT01787162 | Medical University of Graz | — |
| Completed | Safety and Efficacy of POL6326 for Mobilization/Transplant of Sibling Donor in Patients With Hematologic Malig NCT01413568 | Polyphor Ltd. | Phase 1 / Phase 2 |
| Completed | Epidemiological and Clinical-pathological Factors of Philadelphia-negative Myeloproliferative Neoplasms in Ecu NCT05825326 | Sociedad de Lucha Contra el Cáncer del Ecuador | — |
| Terminated | Preservation of Ovarian Function After Hematopoietic Cell Transplant NCT01343368 | Masonic Cancer Center, University of Minnesota | Phase 2 |
| Completed | Post T-plant Infusion of Allogeneic Cytokine Induced Killer (CIK) Cells as Consolidative Therapy in Myelodyspl NCT01392989 | Everett Meyer | Phase 2 |
| Completed | Study of SB939 in Subjects With Myelofibrosis NCT01200498 | M.D. Anderson Cancer Center | Phase 2 |
| Terminated | MSC and HSC Coinfusion in Mismatched Minitransplants NCT01045382 | University of Liege | Phase 2 |
| Terminated | Fludarabine and Busulfan vs. Fludarabine, Busulfan and Total Body Irradiation NCT01366612 | Hackensack Meridian Health | Phase 3 |
| Completed | A Study in Myeloproliferative Disorders NCT01134120 | Eli Lilly and Company | Phase 1 |
| Terminated | Investigation of Dysregulated Signaling in MPD Via Multiparameter Phospho-specific Flow Cytometry NCT01144780 | Stanford University | — |
| Terminated | Efficacy and Safety of a Donor Lymphocyte Preparation Depleted of Functional Host Alloreactive T-cells (ATIR) NCT00967343 | Kiadis Pharma | Phase 2 / Phase 3 |
| Completed | STA-9090 for Treatment of AML, CML, MDS and Myeloproliferative Disorders NCT00858572 | Synta Pharmaceuticals Corp. | Phase 1 |
| Completed | B-Receptor Signaling in Cardiomyopathy NCT01135849 | Daniel Bernstein | — |
| Completed | JAK-STAT Signalling Pathway in Familial Myeloproliferative Disorders NCT00873574 | Assistance Publique - Hôpitaux de Paris | — |
| Enrolling By Invitation | Pathogenesis of Hematologic Malignancies NCT01728402 | OHSU Knight Cancer Institute | — |
| Completed | A Phase 1/2 Study of Oral SB1518 in Subjects With Chronic Idiopathic Myelofibrosis NCT00745550 | S*BIO | Phase 1 / Phase 2 |
| Completed | Investigation of the Cylex® ImmuKnow® Assay NCT00569842 | Indiana University School of Medicine | — |
| Terminated | T-Reg Cell Kinetics, Stem Cell Transplant, REGALE NCT00578539 | Baylor College of Medicine | N/A |
| Terminated | Phase I Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated Cyclophosphamide in NCT00852709 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 1 |
| Terminated | A Safety Study of XL019 in Adults With Myelofibrosis NCT00522574 | Exelixis | Phase 1 |
| Withdrawn | Aprepitant or Ondansetron in Treating Nausea and Vomiting Caused By Opioids in Patients With Cancer NCT00499668 | Vanderbilt-Ingram Cancer Center | N/A |
| Completed | Study With Intravenous Busulfan And Fludarabine Myeloablative Conditioning Regimen For HLA Identical Sibling D NCT01683123 | Grupo Espanol de trasplantes hematopoyeticos y terapia celular | — |
| Completed | Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Tr NCT00787761 | Northside Hospital, Inc. | Phase 2 |
| Terminated | Umbilical Cord Blood (UCB) Transplant, Fludarabine, Melphalan, and Anti-thymocyte Globulin (ATG) in Treating P NCT00827099 | Northside Hospital, Inc. | Phase 2 |
| Completed | A Safety Study of Lintuzumab in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome NCT00283114 | Seagen Inc. | Phase 1 |
| Completed | Busulfan Safety/Efficacy as Conditioning Prior to Hematopoietic Cell Transplantation (HCT) NCT00361140 | H. Lee Moffitt Cancer Center and Research Institute | Phase 4 |
| Terminated | Donor Umbilical Cord Blood Transplant By Injection Into the Bone Marrow in Treating Patients With Hematologic NCT00295880 | Masonic Cancer Center, University of Minnesota | Phase 1 / Phase 2 |
| Completed | Non-Myeloablative Conditioning for Unrelated Donor Umbilical Cord Blood Transplant NCT00305682 | Masonic Cancer Center, University of Minnesota | Phase 2 |
| Completed | Pegasys® in Patients With Myeloproliferative Diseases NCT00452023 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | TLI & ATG for Non-Myeloablative Allogeneic Transplantation for MDS and MPD NCT00185796 | Stanford University | Phase 2 |
| Terminated | Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to T NCT00074490 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Peripheral Blood Stem Cell Transplant vs Bone Marrow Transplant in Individuals With Hematologic Cancers (BMT C NCT00075816 | Medical College of Wisconsin | Phase 3 |
| Completed | Experimental Bone Marrow Transplant Protocol NCT00061581 | National Heart, Lung, and Blood Institute (NHLBI) | Phase 2 |
| Terminated | Minor Histocompatibility Vaccination After Allogeneic Stem Cell Transplantation for Advanced Hematologic Malig NCT00943293 | University of Chicago | Phase 1 |
| Unknown | Study of STI571 in the Treatment of Patients With Idiopathic Hypereosinophilic Syndrome (HES) and Eosinophilic NCT00276926 | University of Bologna | Phase 2 |
| Completed | Non-Myeloablative Allogeneic Transplant for Myelodysplastic Syndromes and Myeloproliferative Disorders NCT00186576 | Stanford University | N/A |
| Completed | Low-Intensity Preparation and Allogeneic Transplant in Patients With Cancers of the Blood NCT00146055 | University of Michigan Rogel Cancer Center | Phase 2 |
| Completed | Evaluation of the Anti-CD-33 Immunotoxin Hum-195/rGel in Patients With Advanced Myeloid Malignancies NCT00038051 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Specialized Blood Cell Transplants for Cancers of the Blood and Bone Marrow NCT00003838 | National Heart, Lung, and Blood Institute (NHLBI) | Phase 2 |
| Completed | Unrelated Stem Cell Transplantation for Adults With Hematopoietic Disorders NCT00511537 | University of California, San Francisco | — |
| Completed | Sibling and Unrelated Donor Hematopoietic Cell Transplant in Hematologic Malignancies NCT00186342 | Stanford University | N/A |